Cargando…
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
BACKGROUND: Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult ge...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798721/ https://www.ncbi.nlm.nih.gov/pubmed/26991780 http://dx.doi.org/10.1371/journal.pone.0150569 |
_version_ | 1782422211014950912 |
---|---|
author | Asselah, Tarik Thompson, Alex J. Flisiak, Robert Romero-Gomez, Manuel Messinger, Diethelm Bakalos, Georgios Shiffman, Mitchell L. |
author_facet | Asselah, Tarik Thompson, Alex J. Flisiak, Robert Romero-Gomez, Manuel Messinger, Diethelm Bakalos, Georgios Shiffman, Mitchell L. |
author_sort | Asselah, Tarik |
collection | PubMed |
description | BACKGROUND: Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple predictive score to identify GT3 patients with a high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV therapy. METHODS: Relationships between baseline characteristics and SVR were explored by multiple logistic regression models and used to develop a simple scoring system to predict SVR using data from 1239 treatment-naive GT3 patients who received PegIFN alfa-2a/RBV for 24 weeks in two large observational cohort studies. RESULTS: The score was validated using a database of 473 patients. Scores were assigned for six factors as follows: age (years) (≤40: 2 points; >40 but ≤55: 1); bodyweight (kg) (<70: 2; ≥70 but <90: 1); no cirrhosis/transition to cirrhosis (2); ALT ≤2.5 x ULN (1); platelets (10(9)/L) (>200: 2; ≥100 but <200: 1); HCV RNA (<400,000 IU/mL: 1). The points are summed to arrive at a score ranging from 0‒10 where higher scores indicate higher chances of SVR; 141, 123, 203, 249, 232, and 218 patients had total scores of 0‒4, 5, 6, 7, 8, and 9–10, respectively, among whom SVR rates were 45%, 62%, 72%, 76%, 84%, and 89%. Among 622 patients who had scores of 6‒10 and HCV RNA <50 IU/mL by treatment week 4 the SVR rate was 86% (532/622). CONCLUSIONS: A simple baseline scoring system involving age, bodyweight, cirrhosis status, ALT level, platelet count and HCV RNA level can be used to identify treatment-naive Caucasian patients with HCV GT3 infection with a high probability of SVR with PegIFN alfa-2a/RBV therapy. |
format | Online Article Text |
id | pubmed-4798721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-47987212016-03-23 A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin Asselah, Tarik Thompson, Alex J. Flisiak, Robert Romero-Gomez, Manuel Messinger, Diethelm Bakalos, Georgios Shiffman, Mitchell L. PLoS One Research Article BACKGROUND: Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple predictive score to identify GT3 patients with a high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV therapy. METHODS: Relationships between baseline characteristics and SVR were explored by multiple logistic regression models and used to develop a simple scoring system to predict SVR using data from 1239 treatment-naive GT3 patients who received PegIFN alfa-2a/RBV for 24 weeks in two large observational cohort studies. RESULTS: The score was validated using a database of 473 patients. Scores were assigned for six factors as follows: age (years) (≤40: 2 points; >40 but ≤55: 1); bodyweight (kg) (<70: 2; ≥70 but <90: 1); no cirrhosis/transition to cirrhosis (2); ALT ≤2.5 x ULN (1); platelets (10(9)/L) (>200: 2; ≥100 but <200: 1); HCV RNA (<400,000 IU/mL: 1). The points are summed to arrive at a score ranging from 0‒10 where higher scores indicate higher chances of SVR; 141, 123, 203, 249, 232, and 218 patients had total scores of 0‒4, 5, 6, 7, 8, and 9–10, respectively, among whom SVR rates were 45%, 62%, 72%, 76%, 84%, and 89%. Among 622 patients who had scores of 6‒10 and HCV RNA <50 IU/mL by treatment week 4 the SVR rate was 86% (532/622). CONCLUSIONS: A simple baseline scoring system involving age, bodyweight, cirrhosis status, ALT level, platelet count and HCV RNA level can be used to identify treatment-naive Caucasian patients with HCV GT3 infection with a high probability of SVR with PegIFN alfa-2a/RBV therapy. Public Library of Science 2016-03-18 /pmc/articles/PMC4798721/ /pubmed/26991780 http://dx.doi.org/10.1371/journal.pone.0150569 Text en © 2016 Asselah et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Asselah, Tarik Thompson, Alex J. Flisiak, Robert Romero-Gomez, Manuel Messinger, Diethelm Bakalos, Georgios Shiffman, Mitchell L. A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin |
title | A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin |
title_full | A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin |
title_fullStr | A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin |
title_full_unstemmed | A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin |
title_short | A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin |
title_sort | predictive model for selecting patients with hcv genotype 3 chronic infection with a high probability of sustained virological response to peginterferon alfa-2a/ribavirin |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798721/ https://www.ncbi.nlm.nih.gov/pubmed/26991780 http://dx.doi.org/10.1371/journal.pone.0150569 |
work_keys_str_mv | AT asselahtarik apredictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT thompsonalexj apredictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT flisiakrobert apredictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT romerogomezmanuel apredictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT messingerdiethelm apredictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT bakalosgeorgios apredictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT shiffmanmitchelll apredictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT asselahtarik predictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT thompsonalexj predictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT flisiakrobert predictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT romerogomezmanuel predictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT messingerdiethelm predictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT bakalosgeorgios predictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin AT shiffmanmitchelll predictivemodelforselectingpatientswithhcvgenotype3chronicinfectionwithahighprobabilityofsustainedvirologicalresponsetopeginterferonalfa2aribavirin |